Compounds > jorunnamycin a
Page last updated: 2024-08-03 02:29:35

jorunnamycin a

Description

jorunnamycin A: structure in first source [MeSH]

jorunnamycin A : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID16043476
CHEMBL ID549905
CHEBI ID188643
MeSH IDM0589633

Synonyms (8)

Synonym
journnamycin a
CHEMBL549905
(1r,2s,10r,12r,13s)-10-(hydroxymethyl)-7,18-dimethoxy-6,17,21-trimethyl-5,8,16,19-tetraoxo-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),17-tetraene-12-carbonitrile
jorunnamycin a
CHEBI:188643
701911-92-4
(6s,7r,9r,14as,15r)-1,5,6,7,9,10,13,14,14a,15-decahydro-9-(hydroxymethyl)-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4h-isoquino[3,2-b][3]benzazocine-7-carbonitrile
DTXSID001098705

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.

Bioassays (62)

Assay IDTitleYearJournalArticle
AID1538830Induction of anoikis in human H460 cells under detachment conditions assessed as decrease in MCL-1 level at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538839Induction of anoikis in human H460 cells harboring with p53 mutant under detachment conditions assessed as effect on P53 level at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538836Inhibition of AKT phosphorylation in human H460 cells under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538864Induction of anoikis in human H23 cells harboring with p53 mutant under detachment conditions assessed as effect on P53 level at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538832Induction of anoikis in human H460 cells under detachment conditions assessed as increase in Bax level at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538819Antiproliferative activity against human H460 cells under detachment conditions assessed as reduction in cell viability at 0.1 to 0.5 uM after 3 hrs by XTT assay2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538869Inhibition of epithelial-mesenchymal transition in human H23 cells harboring with p53 mutant under detachment conditions assessed as decrease in snail protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538816Induction of apoptosis in human H460 cells at 1 uM after 24 hrs by Hoechst 33342/propidium iodide staining based fluorescent microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538822Induction of anoikis in human H460 cells under detachment conditions at 0.05 to 0.5 uM after 24 hrs by Hoechst 33342/propidium iodide staining based fluorescent microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538838Down regulation of caveolin-1 human H460 cells under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538831Induction of anoikis in human H460 cells under detachment conditions assessed as decrease in BCL-2 level at 0.1 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538825Induction of apoptosis in human H460 cells under detachment conditions assessed as late apoptotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 15.44%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID427235Cytotoxicity against human HCT116 cells after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
ISSN: 1464-3391		Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues.
AID1538868Inhibition of epithelial-mesenchymal transition in human H23 cells harboring with p53 mutant under detachment conditions assessed as increase in E-cadherin protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538870Inhibition of epithelial-mesenchymal transition in human H23 cells harboring with p53 mutant under detachment conditions assessed as decrease in vimentin protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538850Induction of apoptosis in human NCI-H292 cells under detachment conditions assessed as early apoptotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 29.96%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538861Induction of anoikis in human H23 cells harboring with p53 mutant under detachment conditions assessed as decrease in MCL-1 level at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538867Inhibition of ERK phosphorylation in human H23 cells harboring with p53 mutant under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538837Inhibition of ERK phosphorylation in human H460 cells under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538865Down regulation of caveolin-1 human H23 cells harboring with p53 mutant under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538821Induction of apoptosis in human H460 cells under detachment conditions assessed as accumulation of necrotic cells at 0.05 to 0.5 uM after 24 hrs by Hoechst 33342/propidium iodide staining based fluorescent microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538835Effect on total ERK protein level in human H460 cells under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538840Inhibition of epithelial-mesenchymal transition in human H460 cells under detachment conditions assessed as increase in E-cadherin protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538855Induction of apoptosis in human H23 cells under detachment conditions assessed as late apoptotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 2.82%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538851Induction of apoptosis in human NCI-H292 cells under detachment conditions assessed as late apoptotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 28.21%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538858Inhibition of colony formation in human NCI-H292 cells under detachment conditions assessed as reduction in size of colonies at 0.1 to 0.5 uM after 14 days by microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538828Inhibition of colony formation in human H460 cells under detachment conditions assessed as reduction in number of colonies at 0.1 to 0.5 uM after 14 days by microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538860Inhibition of colony formation in human H23 cells under detachment conditions assessed as reduction in size of colonies at 0.1 to 0.5 uM after 14 days by microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538853Induction of apoptosis in human H23 cells under detachment conditions assessed as viable cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 69.96%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538863Induction of anoikis in human H23 cells harboring with p53 mutant under detachment conditions assessed as effect on Bax level at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538856Induction of apoptosis in human H23 cells under detachment conditions assessed as necrotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.41%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538866Inhibition of AKT phosphorylation in human H23 cells harboring with p53 mutant under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID427237Cytotoxicity against human QG56 cells at 1.4 to 100 nM after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
ISSN: 1464-3391		Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues.
AID1538871Inhibition of epithelial-mesenchymal transition in human H23 cells harboring with p53 mutant under detachment conditions assessed as increase in claudin-1 protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538847Antiproliferative activity against human H23 cells under detachment conditions assessed as reduction in cell viability at 0.05 to 0.5 uM up to 24 hrs by XTT assay2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538827Induction of anoikis in human H460 cells under detachment conditions assessed as fold change at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538834Effect on total AKT protein level in human H460 cells under detachment conditions at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538813Induction of apoptosis in human H460 cells assessed as accumulation of necrotic cells at 0.05 to 1 uM after 24 hrs by Hoechst 33342/propidium iodide staining based fluorescent microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538846Antiproliferative activity against human NCI-H292 cells under detachment conditions assessed as reduction in cell viability at 0.05 to 0.5 uM up to 24 hrs by XTT assay2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538817Induction of apoptosis in human H460 cells at 0.05 to 0.5 uM after 24 hrs by Hoechst 33342/propidium iodide staining based fluorescent microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538824Induction of apoptosis in human H460 cells under detachment conditions assessed as early apoptotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 22.55%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538862Induction of anoikis in human H23 cells harboring with p53 mutant under detachment conditions assessed as decrease in BCL-2 level at 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538841Inhibition of epithelial-mesenchymal transition in human H460 cells under detachment conditions assessed as decrease in snail protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538859Inhibition of colony formation in human H23 cells under detachment conditions assessed as reduction in number of colonies at 0.1 to 0.5 uM after 14 days by microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538843Inhibition of epithelial-mesenchymal transition in human H460 cells under detachment conditions assessed as increase in claudin-1 protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538829Inhibition of colony formation in human H460 cells under detachment conditions assessed as reduction in size of colonies at 0.1 to 0.5 uM after 14 days by microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538842Inhibition of epithelial-mesenchymal transition in human H460 cells under detachment conditions assessed as decrease in vimentin protein level 0.05 to 0.5 uM after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538826Induction of apoptosis in human H460 cells under detachment conditions assessed as necrotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.58%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538857Inhibition of colony formation in human NCI-H292 cells under detachment conditions assessed as reduction in number of colonies at 0.1 to 0.5 uM after 14 days by microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538815Antiproliferative activity against human H460 cells assessed as reduction in cell viability at 0.05 to 0.5 uM after 24 hrs by MTT assay2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538844Antiproliferative activity against human NCI-H292 cells assessed as reduction in cell viability at 0.05 to 0.5 uM2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID427236Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
ISSN: 1464-3391		Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues.
AID1538833Induction of anoikis in human H460 cells under detachment conditions after 12 hrs by Western blot analysis2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538820Induction of apoptosis in human H460 cells under detachment conditions at 0.05 to 0.5 uM after 24 hrs by Hoechst 33342/propidium iodide staining based fluorescent microscopic method2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538823Induction of apoptosis in human H460 cells under detachment conditions assessed as viable cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 60.43%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538818Antiproliferative activity against human H460 cells under detachment conditions assessed as reduction in cell viability at 0.05 uM after 6 hrs by XTT assay2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538848Induction of anoikis in human H23 cells under detachment conditions assessed as reduction in cell viability at 0.05 uM up to 24 hrs by XTT assay2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538814Antiproliferative activity against human H460 cells assessed as reduction in cell viability at 0.1 to 0.5 uM after at 72 hrs by crystal violet staining assay2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538852Induction of apoptosis in human NCI-H292 cells under detachment conditions assessed as necrotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.28%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538849Induction of apoptosis in human NCI-H292 cells under detachment conditions assessed as viable cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 40.55%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538845Antiproliferative activity against human H23 cells assessed as reduction in cell viability at 0.05 to 0.5 uM2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from
AID1538854Induction of apoptosis in human H23 cells under detachment conditions assessed as early apoptotic cells at 0.5 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 26.81%)2019Journal of natural products, 07-26, Volume: 82, Issue:7
ISSN: 1520-6025		Jorunnamycin A from

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's5 (45.45)24.3611
2020's5 (45.45)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pk 11195
0
aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent00low000000
5-aminoisoquinolinone
0
isoquinolines00low000000
debrisoquin
0
carboxamidine;
isoquinolines		adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent		00low000000
ethaverine
0
isoquinolines00low000000
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide
0
isoquinolines;
sulfonamide		00low000000
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
0
bromobenzenes;
isoquinolines;
olefinic compound;
secondary amino compound;
sulfonamide		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor00low000000
1-(5-isoquinolinesulfonyl)-2-methylpiperazine
0
isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor00low000000
1-(5-isoquinolinesulfonyl)piperazine
0
isoquinolines00low000000
ha 1004
0
isoquinolines00low000000
fasudil
0
isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent		00low000000
hydrocotarnine
0
isoquinolines00low000000
nomifensine
0
isoquinolinesdopamine uptake inhibitor00low000000
6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one
0
isoquinolines00low000000
papaverine
0
benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent		00low000000
praziquantel
0
isoquinolines00low000000
scriptaid
0
isoquinolines00low000000
tilisolol
0
isoquinolines00low000000
cotarnine
0
isoquinolines00low000000
dimethisoquin
0
isoquinolines00low000000
1,2,3,4-tetrahydroisoquinoline
0
isoquinolines00low000000
isoquinoline
0
azaarene;
isoquinolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene		00low000000
cepharanthine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
bicuculline
0
benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin		00low000000
isocarbostyril
0
isoquinolines00low000000
salsolidine
0
isoquinolines00low000000
laudanosine
0
isoquinolines00low000000
1-methylisoquinoline
0
isoquinolines00low000000
heliamine
0
aromatic ether;
diether;
isoquinoline alkaloid;
isoquinolines		plant metabolite00low000000
1,2-dehydrosalsolinol
0
isoquinolines00low000000
dehydroemetine
0
aromatic ether;
isoquinolines;
pyridoisoquinoline		antileishmanial agent;
antimalarial;
antiprotozoal drug		00low000000
metocurine
0
isoquinolines00low000000
thalicarpine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
dimoxyline
0
isoquinolines00low000000
6,7-Dimethoxy-1-methyl-3,4-dihydroisoquinoline
0
isoquinolines00low000000
coralyne
0
isoquinolines00low000000
(3R)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3H-isobenzofuran-1-one
0
isoquinolines00low000000
salsoline
0
isoquinolines00low000000
isosalsoline
0
isoquinolines00low000000
amonafide
0
isoquinolines00low000000
daurisoline
0
isoquinolines00low000000
magnocurarine
0
isoquinolines00low000000
quinapril
0
dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug		00low000000
tretoquinol
0
isoquinolines00low000000
moxaverine
0
isoquinolines00low000000
tritoqualine
0
isoquinolines00low000000
tubulosine
0
beta-carbolines;
isoquinoline alkaloid;
isoquinolines;
phenols;
secondary amino compound;
tertiary amino compound		00low000000
hernandezine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
tetrandrine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
dauricine
0
aromatic ether;
bisbenzylisoquinoline alkaloid;
isoquinolines;
phenols;
tertiary amino compound		plant metabolite00low000000
cherylline
0
isoquinolines00low000000
gliquidone
0
isoquinolines00low000000
1-methyl-1,2,3,4-tetrahydroisoquinoline
0
isoquinolines00low000000
laudanosoline
0
isoquinolines00low000000
papaveraldine
0
isoquinolines00low000000
corydaline
0
isoquinoline alkaloid;
isoquinolines		00low000000
4-hydroxydebrisoquin
0
carboxamidine;
isoquinolines;
secondary alcohol		metabolite00low000000
quinaprilat
0
dicarboxylic acid;
isoquinolines;
tertiary carboxamide		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent		00low000000
cycleanine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
dihydrotetrabenazine
0
isoquinolines00low000000
7,8-dichloro-1,2,3,4-tetrahydroisoquinoline
0
isoquinolines;
organochlorine compound		00low000000
1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline
0
isoquinolines00low000000
cki 7
0
isoquinolines;
organochlorine compound;
primary amino compound;
sulfonamide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor00low000000
pixantrone
0
isoquinolines00low000000
isodibut
0
isoquinolines00low000000
3,4-dihydro-5-methyl-1(2h)-isoquinolinone
0
isoquinolines00low000000
solifenacin
0
isoquinolines00low000000
liensinine
0
isoquinolines00low000000
trilobine
0
isoquinolines00low000000
corynoline
0
benzophenanthridine alkaloid;
cyclic acetal;
isoquinolines;
organic heterohexacyclic compound;
secondary alcohol		antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hepatoprotective agent;
metabolite		00low000000
minalrestat
0
isoquinolines00low000000
hydrastine
0
isoquinolinesmetabolite00low000000
pronuciferine
0
aromatic ether;
cyclic ketone;
isoquinoline alkaloid;
isoquinolines;
organic heterotetracyclic compound		plant metabolite00low000000
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
0
isoquinolines00low000000
solifenacin succinate
0
isoquinolines00low000000
berbamine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
2-(2-oxolanylmethyl)benzo[de]isoquinoline-1,3-dione
0
isoquinolines00low000000
guatteguamerine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
korupensamine-b
0
isoquinolines;
naphthalenes		00low000000
obamegine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
hydrastine hydrochloride, (s-(r*,s*))-isomer
0
isoquinolines00low000000
narcotoline
0
isoquinolines00low000000
oxyacanthine
0
bisbenzylisoquinoline alkaloid;
isoquinolines;
macrocycle;
phenols;
tertiary amino compound		00low000000
floxacillin
0
isoquinolines00low000000
dioncophylline a
0
biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes;
naphthalenes		antifungal agent;
antimalarial;
metabolite;
molluscicide		00low000000
dioncophylline c
0
aromatic ether;
biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes;
naphthols		antimalarial;
antiplasmodial drug;
metabolite		00low000000
h 1152
0
isoquinolines;
N-sulfonyldiazepane		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor00low000000
9,10-dimethoxy-2,4,6,7-tetrahydro-[1,3]oxazino[4,3-a]isoquinoline-1-carbonitrile
0
isoquinolines00low000000
hydrastine, (r-(r*,s*))-isomer
0
isoquinolines00low000000
6,7-dimethoxy-N-(4-methylphenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-2-carboxamide
0
isoquinolines00low000000
5-(3,4-dihydro-1H-isoquinolin-2-yl)-2-(2-furanyl)-4-oxazolecarbonitrile
0
isoquinolines00low000000
1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-2-phenyl-1-butanone
0
isoquinolines00low000000
methyl isoquinoline-3-carboxylate
0
isoquinolines00low000000
1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-(2-fluorophenoxy)ethanone
0
isoquinolines00low000000
1-spiro[2,4-dihydroisoquinoline-3,1'-cyclohexane]thione
0
isoquinolines00low000000
N-(4-methoxyphenyl)-3,4-dihydro-1H-isoquinoline-2-carbothioamide
0
isoquinolines00low000000
N-(4-fluorophenyl)-3,4-dihydro-1H-isoquinoline-2-carboxamide
0
isoquinolines00low000000
3-amino-2-(4-methoxyphenyl)-7-nitro-1-oxo-4-isoquinolinecarbonitrile
0
isoquinolines00low000000
4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-(2,6-dimethylphenyl)benzamide
0
isoquinolines00low000000
LSM-16526
0
isoquinolines00low000000
drotaverin
0
isoquinolines00low000000
5,5-diethyl-1-[oxo(1-piperidinyl)methyl]-6H-pyrrolo[2,1-a]isoquinoline-2,3-dione
0
isoquinolines00low000000
N-(4-fluorophenyl)-2-(5-methoxy-1-oxo-2-isoquinolinyl)acetamide
0
isoquinolines00low000000
2-[[1-oxo-2-[2-oxo-2-(1-piperidinyl)ethyl]-5-isoquinolinyl]oxy]acetic acid ethyl ester
0
isoquinolines00low000000
2-[[2-[2-(2,3-dihydroindol-1-yl)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]acetic acid ethyl ester
0
isoquinolines00low000000
5-[[2-[(3-methylphenyl)methyl]-1-oxo-3,4-dihydroisoquinolin-5-yl]oxymethyl]-2-furancarboxylic acid methyl ester
0
isoquinolines00low000000
5-[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethoxy]-2-[(3-methylphenyl)methyl]-3,4-dihydroisoquinolin-1-one
0
isoquinolines00low000000
4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-[4-(1-pyrrolidinylsulfonyl)phenyl]benzamide
0
isoquinolines00low000000
4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-[4-(1-piperidinylsulfonyl)phenyl]benzamide
0
isoquinolines00low000000
1-(5-isoquinolinyl)-3-(2-phenylethyl)thiourea
0
isoquinolines00low000000
1-(4-ethoxyphenyl)-3-(5-isoquinolinyl)thiourea
0
isoquinolines00low000000
4-[[5-(difluoromethylthio)-4-methyl-1,2,4-triazol-3-yl]methoxy]-5-methylisoquinoline
0
isoquinolines00low000000
2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]thio]-3-ethyl-5,6-dimethyl-4-thieno[2,3-d]pyrimidinone
0
isoquinolines00low000000
N-[6-amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-2-(3,4-dihydro-1H-isoquinolin-2-yl)-N-(2-methoxyethyl)acetamide
0
isoquinolines00low000000
2-(Methylamino)-2,3-dihydro-1H-benzo[de]isoquinoline-1,3-dione
0
isoquinolines00low000000
3-[3-(1,3-dioxo-2-benzo[de]isoquinolinyl)propylthio]propanoic acid
0
isoquinolines00low000000
4-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-(1,1-dioxo-3-thiolanyl)butanamide
0
isoquinolines00low000000
2-[4-(3,4-dihydro-1H-isoquinolin-2-yl)-4-oxobutyl]benzo[de]isoquinoline-1,3-dione
0
isoquinolines00low000000
4-bromobenzenesulfonic acid (1,3-dioxo-2-benzo[de]isoquinolinyl) ester
0
isoquinolines00low000000
2-(3-hydroxyphenyl)-6-(1-piperidinyl)benzo[de]isoquinoline-1,3-dione
0
isoquinolines00low000000
2-[3-(1H-1,2,4-triazol-5-ylthio)propyl]benzo[de]isoquinoline-1,3-dione
0
isoquinolines00low000000
2-[2-[4-[2-hydroxy-3-(2-methylphenoxy)propyl]-1-piperazinyl]ethyl]benzo[de]isoquinoline-1,3-dione
0
isoquinolines00low000000
2-benzoyl-N-(6-methoxy-3-pyridinyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide
0
isoquinolines00low000000
mcn 5652
0
isoquinolines00low000000
3-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-methyl-N-(6-methyl-2-pyridinyl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
0
isoquinolines00low000000
4-[(4-cyclohexyl-1-piperazinyl)-oxomethyl]-2-ethyl-6,7-dimethoxy-1-isoquinolinone
0
isoquinolines00low000000
1-[[1-(2-methoxyanilino)-4-isoquinolinyl]-oxomethyl]-4-piperidinecarboxamide
0
isoquinolines00low000000
3,4-dihydro-1H-isoquinolin-2-yl-(1-ethylsulfonyl-4-piperidinyl)methanone
0
isoquinolines00low000000
1-cyclopentyl-N-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-5-oxo-3-pyrrolidinecarboxamide
0
isoquinolines00low000000
3-(3,4-dimethoxyphenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
0
isoquinolines00low000000
1-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(4-ethylphenyl)urea
0
isoquinolines00low000000
6,7-dimethoxy-N-[(5-methyl-2-furanyl)methyl]-2-(2-methylpropyl)-1-oxo-4-isoquinolinecarboxamide
0
isoquinolines00low000000
4-[[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-7-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-2-yl]methyl]morpholine
0
isoquinolines00low000000
5-[3,4-dihydro-1H-isoquinolin-2-yl(phenyl)methyl]-6-thiazolo[3,2-b][1,2,4]triazolol
0
isoquinolines00low000000
4-chloro-N-[1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-methylpropan-2-yl]benzenesulfonamide
0
isoquinolines00low000000
5-[2-[3-(4-fluorophenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-2-oxoethoxy]-2-(phenylmethyl)-3,4-dihydroisoquinolin-1-one
0
isoquinolines00low000000
2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester
0
isoquinolines00low000000
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(4-fluorophenyl)-2-(2-methoxyethyl)-1-oxo-3,4-dihydroisoquinoline-4-carboxamide
0
isoquinolines00low000000
2-[[2-[2-(4-methoxyanilino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester
0
isoquinolines00low000000
2-(4-chlorophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
0
isoquinolines00low000000
4-phenyl-1,2,3,4-tetrahydroisoquinoline
0
isoquinolines00low000000
6,7-dimethoxy-N-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxamide
0
isoquinolines00low000000
8-nitro-5-[3-(trifluoromethyl)-1-piperidinyl]isoquinoline
0
isoquinolines00low000000
2-(3-methyl-1-oxo-2-isoquinolinyl)-N-(3,4,5-trimethoxyphenyl)acetamide
0
isoquinolines00low000000
8-hydroxymanzamine a
0
alkaloid;
beta-carbolines;
isoquinolines		anti-HSV-2 agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
metabolite		00low000000
isoliensinine
0
isoquinolines00low000000
mivacurium
0
isoquinolines00low000000
bw b1090u
0
isoquinolines00low000000
3,4-dihydro-1H-isoquinolin-2-yl-(4-ethyl-5-thieno[3,2-b]pyrrolyl)methanone
0
isoquinolines00low000000
papaveroline
0
isoquinolines00low000000
norbinaltorphimine
0
isoquinolines00low000000
naltrindole
0
isoquinolines00low000000
manzamine a
0
alkaloid;
beta-carbolines;
isoquinolines		animal metabolite;
anti-HSV-1 agent;
antimalarial;
antineoplastic agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
marine metabolite		00low000000
2-(2-phenylethyl)benzo[de]isoquinoline-1,3-dione
0
isoquinolines00low000000
ripasudil
0
isoquinolines00low000000
ancistroealaine a
0
aromatic ether;
biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes		antileishmanial agent;
antiplasmodial drug;
metabolite;
trypanocidal drug		00low000000
SIS3 free base
0
aromatic ether;
enamide;
isoquinolines;
monocarboxylic acid amide;
pyrrolopyridine;
tertiary carboxamide		Smad3 inhibitor00low000000
fg-4592
0
aromatic ether;
isoquinolines;
N-acylglycine		EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor		00low000000
sar 1118
0
1-benzofurans;
isoquinolines;
L-phenylalanine derivative;
N-acyl-L-alpha-amino acid;
sulfone		anti-inflammatory drug;
lymphocyte function-associated antigen-1 antagonist		00low000000
4-(4-chlorophenyl)sulfonyl-5-(3,4-dihydro-1H-isoquinolin-2-yl)-2-ethylsulfonylthiazole
0
isoquinolines00low000000
bebeerine
0
bisbenzylisoquinoline alkaloid;
isoquinolines		00low000000
(1S)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-2-oxido-3,4-dihydro-1H-isoquinolin-2-ium-7-ol
0
isoquinolines;
tertiary amine oxide		00low000000
dihydrotetrabenazine, (2alpha,3beta,11bbeta)-isomer
0
isoquinolines00low000000
1-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-3-(4-nitrophenyl)urea
0
isoquinolines00low000000
2-(1,3-benzodioxol-5-ylmethyl)-6,7-dimethoxy-1-methyl-3,4-dihydro-1H-isoquinoline
0
isoquinolines00low000000
N-(3-nitrophenyl)-3,4-dihydro-1H-isoquinoline-2-carboxamide
0
isoquinolines00low000000
2-(5-butoxy-1-oxo-2-isoquinolinyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)acetamide
0
isoquinolines00low000000
almorexant
0
isoquinolines00low000000
ipi-145
0
isoquinolines00low000000
nbi 31772
0
aromatic ketone;
benzenediols;
hydroxy monocarboxylic acid;
isoquinolines;
tetrol		insulin-like growth factor-binding protein inhibitor00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
jorumycin
1
2009200915.0medium000100
renieramycin m
1
2009200915.0low000100
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
aspartic acid
1
aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter		202020204.0low000010
carbostyril
8
monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite201320215.8high000071
tyrosine
1
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical		2013201311.0low000010
kainic acid
1
dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist		202020204.0low000010
podophyllotoxin
1
furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator		202020204.0low000010
1,2,3,4-tetrahydroquinoline
1
quinolines202020204.0low000010
saframycin a
2
201820205.0medium000020
aspergillomarasmine a
1
202020204.0medium000010
jorumycin
2
201320198.0high000020
renieramycin m
2
201620206.0medium000020
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Adverse Drug Event0
1
202320231.0low000001
Bladder Cancer0
1
202320231.0low000001
Breast Cancer0
1
2009200915.0low000100
Breast Neoplasms0
1
2009200915.0low000100
Cancer of Colon0
1
2009200915.0low000100
Cancer of Lung0
3
201920223.3medium000012
Carcinoma0
2
200920238.0low000101
Carcinoma, Anaplastic0
2
200920238.0low000101
Carcinoma, Non-Small Cell Lung0
2
201620225.0low000011
Carcinoma, Non-Small-Cell Lung0
2
201620225.0low000011
Colonic Neoplasms0
1
2009200915.0low000100
Drug-Related Side Effects and Adverse Reactions0
1
202320231.0low000001
Lung Neoplasms0
3
201920223.3medium000012
Urinary Bladder Neoplasms0
1
202320231.0low000001

Safety/Toxicity (2)

ArticleYear
Chemistry of Renieramycins. 15. Synthesis of 22-O-Ester Derivatives of Jorunnamycin A and Their Cytotoxicity against Non-Small-Cell Lung Cancer Cells.
Journal of natural products, , 08-26, Volume: 79, Issue:8		2016
Chemistry of renieramycins. Part 8: synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues.
Bioorganic & medicinal chemistry, , Jul-01, Volume: 17, Issue:13		2009